These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14725487)

  • 1. Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol.
    Drugs R D; 2004; 5(1):25-7. PubMed ID: 14725487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease.
    Madaan A
    Drugs Today (Barc); 2009 Jan; 45(1):3-9. PubMed ID: 19271027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.
    Prenner BM
    Expert Opin Pharmacother; 2007 Dec; 8(17):3069-84. PubMed ID: 18001266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
    Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.
    Loh CH; Donohue JF; Ohar JA
    Expert Opin Drug Saf; 2015 Mar; 14(3):463-72. PubMed ID: 25563342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of arformoterol in the management of COPD.
    King P
    Int J Chron Obstruct Pulmon Dis; 2008; 3(3):385-91. PubMed ID: 18990965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eszopiclone: esopiclone, estorra, S-zopiclone, zopiclone--Sepracor.
    Drugs R D; 2005; 6(2):111-5. PubMed ID: 15777104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma.
    Newnham DM; McDevitt DG; Lipworth BJ
    Am J Med; 1994 Jul; 97(1):29-37. PubMed ID: 7913292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
    Ganapathy V; Stensland MD
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1793-1801. PubMed ID: 28694692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
    Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
    Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arformoterol tartrate in the treatment of COPD.
    Cazzola M; Hanania NA; Matera MG
    Expert Rev Respir Med; 2010 Apr; 4(2):155-62. PubMed ID: 20406080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
    Donohue JF; Hanania NA; Make B; Miles MC; Mahler DA; Curry L; Tosiello R; Wheeler A; Tashkin DP
    Chest; 2014 Dec; 146(6):1531-1542. PubMed ID: 25451347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.
    Chen YJ; Makin C; Bollu VK; Navaie M; Celli BR
    J Med Econ; 2016; 19(1):11-20. PubMed ID: 26357881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formoterol delivered by Turbuhaler: in pediatric asthma.
    Cheer SM; Warner GT; Easthope SE
    Paediatr Drugs; 2003; 5(1):63-8; discussion 69. PubMed ID: 12513109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.
    Bartow RA; Brogden RN
    Drugs; 1998 Feb; 55(2):303-22. PubMed ID: 9506248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchodilator effect of single-dose formoterol administered by pressurized metered-dose inhaler in children with asthma aged 6 to <12 years receiving budesonide.
    Berger WE; Gillen M; Eckerwall G; Uryniak T; Trudo FJ; Lampl KL
    Allergy Asthma Proc; 2014; 35(2):134-40. PubMed ID: 24717790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined budesonide/formoterol turbuhaler treatment of asthma.
    Remington TL; Heaberlin AM; DiGiovine B
    Ann Pharmacother; 2002 Dec; 36(12):1918-28. PubMed ID: 12452756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
    Corren J; Mansfield LE; Pertseva T; Blahzko V; Kaiser K
    Respir Med; 2013 Feb; 107(2):180-95. PubMed ID: 23273405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.